Related Experiment Video
Updated: Jun 28, 2026
08:13
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
5.5K
Exosomes in Myasthenia Gravis-Review
Krystian Ejdys1, Marcin P Mycko1
1Department of Neurology and Neurosurgery, Laboratory of Neuroimmunology, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland.
Cells
|April 27, 2026
Summary
Myasthenia gravis (MG) involves immune attacks on the neuromuscular junction. This review explores how blood exosomes may play a role in MG and serve as potential biomarkers for this rare autoimmune disorder.
Area of Science:
- Neuroimmunology
- Extracellular Vesicle Biology
Background:
- Myasthenia gravis (MG) is a rare autoimmune neuromuscular junction disorder.
- Autoantibodies targeting postsynaptic membrane proteins cause muscle weakness and fatigue in MG.
- Current therapies improve management, but disease mechanisms and biomarkers require further investigation.
Purpose of the Study:
- To review the current evidence on the role of exosomes in myasthenia gravis.
- To discuss the potential utility of exosomes as biomarkers for MG.
- To highlight future research directions in exosome-based MG research.
Main Methods:
- Literature review of studies investigating exosomes in MG.
- Analysis of exosome composition and function in autoimmune diseases.
- Evaluation of exosome potential as diagnostic and prognostic markers.
Main Results:
- Exosomes are involved in intercellular communication and material transfer.
- Circulating exosomes may reflect immune status and disease processes in MG.
- Exosomes show promise as minimally invasive biomarkers for MG.
Conclusions:
- Exosomes are implicated in the pathogenesis of myasthenia gravis.
- Blood-derived exosomes represent a potential source for novel MG biomarkers.
- Further research is needed to validate exosome utility in MG diagnosis and management.
Related Concept Videos
01:36Overview of Exosomes
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...